Navigation Links
AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Date:1/28/2010

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term future looks strong.

"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."

The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email

SOURCE AstraZeneca Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
2. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
3. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
4. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
7. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
8. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
9. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
10. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  U.S. biotech company Kultevat ... exclusive license for technology developed by the Donald ... in plants, including for applications in production of natural ... The technology was developed under the direction of ... and former president of the Danforth Plant Science Center, ...
(Date:9/18/2014)... Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... announced concurrent but separate underwritten offerings of 10,000,000 shares ... public of $2.00 per share, for expected gross proceeds ... A Convertible Preferred Stock at a price to the ... of $20 million. Each share of Series A Convertible ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
Breaking Biology Technology:Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2
... ... ... ... March 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the ...
... LAKE, N.J. , March 11 Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen ... , ... , , ... ...
... China , March 11 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. ... ("TCM") based in Chengdu, China , today,announced it will present ... held March 15-17, 2010 in Dana Point, California ... Tuesday, March 16, 2010, ...
Cached Biology Technology:Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 3Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 4Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 5Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 6Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 7Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 8Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 9Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 10FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 2Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 3Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 4
(Date:9/17/2014)... (Sept. 17, 2014) A rare genetic disorder known as ... a recent joint investigation by researchers at San Diego ... In addition to suggesting better treatment options for people ... into the genetic underpinnings of autism., Jacobsen syndrome affects ... Institutes of Health. It occurs in a person when ...
(Date:9/17/2014)... Mar Medical Research Institute) and at the Universitat Politcnica ... eLife showing that RNA called non-coding (IncRNA) ... proteins, some of which could have important cell functions ... instructions found in an RNA molecule. However, only 2% ... the synthesis of proteins, meaning it is coding. Other ...
(Date:9/17/2014)... 17, 2014 Researchers at UTSouthwestern Medical Center have ... protein apolipoprotein E, called apoE3, helps repair the lining ... do not get the benefit of this repair, putting ... believe that we have identified one mechanism by which ... genetic variant, apoE4, is detrimental," said Dr. Philip ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... and use of commercial fertilisers and animal waste is ... our aquatic environment. Yet global food and bioenergy supplies ... Agriculture and Ecology at LIFE Faculty of Life ... massive resources at the development of sustainable animal waste ...
... a popular species of game fish in Lake Erie are ... most comprehensive to date on mercury levels in Great Lakes ... a semi-monthly journal. Satyendra Bhavsar and colleagues note ... lakes in the world. The lakes are of significant economic ...
... 20, 2010) -- The Howard Hughes Medical Institute (HHMI) ... Rice University,s successful undergraduate global health program Beyond Traditional ... million HHMI grant in 2006, challenges students to come ... developing world. The program has captured the imagination of ...
Cached Biology News:Massive resources now directed at sustainable animal waste technology 2HHMI renews grant for Rice's global health program 2
...
TNM-FH Insect Medium 1 liter...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Biology Products: